People: Genomic Health Inc (GHDX.O)

Summary

Name	Age	Since	Current Position
Kimberly Popovits	54	2012	Chairman of the Board, President, Chief Executive Officer
Dean Schorno	50	2011	Chief Financial Officer
G. Bradley Cole	57	2012	Chief Operating Officer
Steven Shak	62	2012	Executive Vice President - Research and Development, Chief Medical Officer
Kathy Hibbs	49	2012	Senior Vice President, General Counsel, Secretary
Julian Baker	45	2012	Lead Independent Director
Felix Baker	44	2012	Director
Fred Cohen	56	2002	Independent Director
Samuel Colella		2001	Independent Director
Ginger Graham	56	2008	Independent Director
Randall Livingston	58	2004	Independent Director
Woodrow Myers	58	2006	Independent Director

» Insider Trading

Biographies

Name	Description
Kimberly Popovits	Ms. Kimberly J. Popovits is Chairman of the Board, President, Chief Executive Officer of Genomic Health Inc. She has served as President and Chief Executive Officer since January 2009, and as Chairman of the Board since March 1, 2012. Prior to that, Ms. Popovits served as President and Chief Operating Officer from February 2002 to January 2009. From November 1987 to February 2002, Ms. Popovits served in various roles at Genentech, Inc., a biotechnology company, most recently serving as Senior Vice President, Marketing and Sales from February 2001 to February 2002, and as Vice President, Sales from October 1994 to February 2001. Prior to joining Genentech, Ms. Popovits served as Division Manager, Southeast Region, for American Critical Care, a Division of American Hospital Supply, a supplier of healthcare products to hospitals. In addition, Ms. Popovits served as a director of Nuvelo, Inc. from July 2005 until its merger with ARCA biopharma, Inc. in January 2009. Ms. Popovits holds a B.A. in Business from Michigan State University.
Dean Schorno	Mr. Dean L. Schorno is Chief Financial Officer of Genomic Health Inc., since January 3, 2011. He served as the Company’s Senior Vice President - Finance from February 2010, Vice President, Finance from August 2008 until February 2010, and as Vice President, Operations from January 2004 until August 2008. From July 2001 through December 2003, he led the Company's finance group as a Director and then Senior Director. Before joining Genomic Health, from 1991 through 2001, Mr. Schorno headed an accounting and consulting firm, which he founded. From 1985 to 1991, Mr. Schorno worked at an international accounting firm. Mr. Schorno holds a B.S in Business Administration from the University of California, Berkeley and is a Certified Public Accountant.
G. Bradley Cole	Mr. G. Bradley Cole is Chief Operating Officer of Genomic Health Inc. He has served as Chief Operating Officer since January 2009, and also served as Chief Financial Officer from July 2004 until January 2011. Prior to that, Mr. Cole served as Executive Vice President, Operations from January 2008 and as Executive Vice President and Chief Financial Officer from July 2004 until January 2009. Mr. Cole also served as Secretary from February 2005 until July 2012. From December 1997 to May 2004, he served in various roles at Guidant Corporation, a medical device company, most recently serving as Vice President, Finance and Business Development for the Endovascular Solutions Group from January 2001 until May 2004. From July 1994 to December 1997, Mr. Cole was Vice President, Finance and Chief Financial Officer of Endovascular Technologies, Inc., a medical device company that was acquired by Guidant Corporation. From December 1988 to February 1994, he served as Vice President, Finance and Chief Financial Officer of Applied Biosystems Incorporated, a life sciences systems company. Mr. Cole holds a B.S. in Business from Biola University and an M.B.A. from San Jose State University.
Steven Shak	Dr. Steven Shak, M.D., is Executive Vice President - Research and Development, Chief Medical Officer of Genomic Health Inc. From July 1996 to October 2000, Dr. Shak served in various roles in Medical Affairs at Genentech, most recently as Senior Director and Staff Clinical Scientist. From November 1989 to July 1996, Dr. Shak served as a Director of Discovery Research at Genentech, where he was responsible for Pulmonary Research, Immunology, and Pathology. Prior to joining Genentech, Dr. Shak was an Assistant Professor of Medicine and Pharmacology at the New York University School of Medicine. Dr. Shak holds a B.A. in Chemistry from Amherst College and an M.D. from the New York University School of Medicine, and completed his post-doctoral training at the University of California, San Francisco.
Kathy Hibbs	Ms. Kathy L. Hibbs is Senior Vice President, General Counsel and Secretary of Genomic Health Inc. She has served as Senior Vice President and General Counsel since December 2009. Ms. Hibbs has also served as Secretary since July 2012. From February 2007 to August 2009, Ms. Hibbs served as a Senior Vice President and General Counsel of Monogram Biosciences, Inc., a developer of products to help guide and improve the treatment of infectious diseases, cancer and other serious diseases, and Ms. Hibbs served as Vice President and General Counsel of Monogram from April 2001 until February 2007. From 1994 to 2001, Ms. Hibbs held corporate counsel positions at Multitude, Inc., Varian Medical Systems and First Nationwide Bank. Ms. Hibbs holds a J.D. from the University of California, Hastings School of Law, and a B.A. in Political Science from the University of California, Riverside and is licensed to practice law in California.
Julian Baker	Dr. Julian C. Baker has been appointed as Lead Independent Director of Genomic Health, Inc., effective March 1, 2012. He is a Managing Partner of Baker Brothers Investments, which he and his brother, Felix Baker, Ph.D., founded in 2000. Mr. Baker's firm manages a family of long-term investment funds for university endowments and foundations, which are focused on publicly traded life sciences companies. Mr. Baker's career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Previously, Mr. Baker was employed from 1988 to 1993 by the private equity investment arm of Credit Suisse First Boston Corporation. Mr. Baker is also a director of Incyte Corporation. In addition, Mr. Baker served as a director of Neurogen Corporation from May 1999 until its acquisition in December 2009, a director of Theravance, Inc. from January 1999 to April 2007 and a director of Trimeris, Inc. from April 2004 until November 2011. Mr. Baker holds an A.B. in Social Studies from Harvard University.
Felix Baker	Dr. Felix J. Baker, Ph.D., is appointed as the Director of Genomic Health, Inc. Dr. Baker’s career as a fund-manager began in 1994 when he co-founded a biotechnology investing partnership with the Tisch Family. Dr. Baker holds a B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school. Dr. Baker currently serves as a director of Seattle Genetics, Inc. and Synageva BioPharma Corp., both of which are publicly-traded biotechnology companies. In addition, Dr. Baker previously served as a director of AnorMED Inc., Ardea BioSciences, Inc., ConjuChem, Biotechnologies Inc., Neurogen Corporation and Trimeris, Inc., all of which were publicly-traded companies during Dr. Baker’s service as a director.
Fred Cohen	Dr. Fred E. Cohen, M.D., D.Phil., is Independent Director of Genomic Health, Inc. He is a partner at TPG, a private equity firm he joined in 2001, and serves as co-head of TPG’s biotechnology group. Dr. Cohen is also a Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, where he has taught since 1988. Dr. Cohen serves as a director of Axcan Pharmaceuticals, Quintiles Transnational and a number of other privately held companies. Dr. Cohen holds a B.S. in Molecular Biophysics and Biochemistry from Yale University, a D.Phil. in Molecular Biophysics from Oxford University and an M.D. from Stanford University.
Samuel Colella	Mr. Samuel D. Colella is Independent Director of Genomic Health, Inc. He is a Managing Director of Versant Ventures, a healthcare and biotechnology venture capital firm he co-founded in 1999. Mr. Colella is also a general partner of Institutional Venture Partners, a venture capital firm he joined in 1984. Mr. Colella currently serves as the Chairman of the Board of Fluidigm Corporation and as a director of Alexza Pharmaceuticals, Inc., and a number of privately held technology and biotechnology companies. In addition, Mr. Colella served as a director of Thermage, Inc. from September 1997 to July 2007, as a director of Symyx Technologies, Inc. from August 1997 to June 2007, and as a director of Jazz Pharmaceuticals, Inc. from 2004 to January 2012. Mr. Colella holds a B.S. in Business and Engineering from the University of Pittsburgh and an M.B.A. from the Stanford Graduate School of Business.
Ginger Graham	Ms. Ginger L. Graham is Independent Director of Genomic Health, Inc. She has served as Faculty at Harvard Business School since October 2009 and as President and Chief Executive Officer of Two Trees Consulting, a healthcare and executive leadership consulting firm, since November 2007. Ms. Graham was Chief Executive Officer of Amylin Pharmaceuticals, Inc., a biopharmaceutical company, from September 2003 to March 2007, and served as Amylin's President from September 2003 to June 2006. From 1994 to 2003, Ms. Graham held various positions with Guidant Corporation, including Group Chairman, Office of the President, President of the Vascular Intervention Group, and Vice President. From 1979 to 1994, Ms. Graham held various positions with Eli Lilly and Company, including President and Chief Executive Officer of Advanced Cardiovascular Systems, Inc. Ms. Graham currently serves as a director of Walgreen Co. and a number of privately held companies. In addition, Ms. Graham served as a director of Amylin Pharmaceuticals, Inc. from November 1995 to May 2009, and as a director of Millenium Pharmaceuticals, Inc. from February 2002 to January 2004. Ms. Graham holds a B.S. in Agricultural Economics from the University of Arkansas and an M.B.A. from Harvard University.
Randall Livingston	Mr. Randall S. Livingston is Independent Director of Genomic Health, Inc. He has served as Vice President for Business Affairs and Chief Financial Officer of Stanford University since 2001. Prior to 2001, Mr. Livingston spent 16 years working in Silicon Valley with several technology and life science companies as Chief Financial Officer and in various corporate development and marketing roles. Mr. Livingston currently serves as a director of eHealth, Inc. and Pacific Biosciences, Inc. Mr. Livingston holds a B.S. in Mechanical Engineering from Stanford University and an M.B.A. from the Stanford Graduate School of Business.
Woodrow Myers	Dr. Woodrow A. Myers, Jr., M.D., is Independent Director of Genomic Health, Inc. He has served as Managing Director of Myers Ventures LLC, which concentrates on opportunities in healthcare and education, since December 2005. He was the Executive Vice President and Chief Medical Officer of WellPoint, Inc., a commercial health benefits company, from September 2000 to January 2005. Dr. Myers currently serves as a director of Express Scripts Holding Company and Liposcience, Inc., and serves as Chairman of the Board of the Mozambique Healthcare Consortium. In addition, Dr. Myers served as a director of ThermoGenesis Corp from June 2006 to December 2009, and as a director of CardioNet, Inc. from August 2007 to May 2009. Dr. Myers holds a B.S. in Biological Sciences from Stanford University, an M.D. from Harvard Medical School and an M.B.A. from the Stanford Graduate School of Business.

Basic Compensation

Name	Fiscal Year Total
Kimberly Popovits	1,833,600
Dean Schorno	837,157
G. Bradley Cole	1,344,650
Steven Shak	1,051,430
Kathy Hibbs	--
Julian Baker	--
Felix Baker	--
Fred Cohen	--
Samuel Colella	--
Ginger Graham	--
Randall Livingston	--
Woodrow Myers	--

As Of 30 Dec 2011

Options Compensation

Name	Options	Value
Kimberly Popovits	194,692	1,486,933
Dean Schorno	1,276	23,218
G. Bradley Cole	263,370	2,537,799
Steven Shak	169,348	1,389,810
Kathy Hibbs	0	0
Julian Baker	0	0
Felix Baker	0	0
Fred Cohen	0	0
Samuel Colella	0	0
Ginger Graham	0	0
Randall Livingston	0	0
Woodrow Myers	0	0

Insider Trading

Name	Shares Traded	Price
LIVINGSTON RANDALL S	1,337	$1.33
LIVINGSTON RANDALL S	1,337	$35.83
BAKER FELIX J	2,985	$35.53
BAKER FELIX J	23,610	$35.53
BAKER FELIX J	589	$35.53
BAKER FELIX J	44,244	$34.75
POPOVITS KIMBERLY J	2,500	$2.88
HIBBS KATHY L	1,250	$21.07
POPOVITS KIMBERLY J	2,500	$34.40
BAKER FELIX J	140,962	$34.02
POPOVITS KIMBERLY J	2,500	$2.88
POPOVITS KIMBERLY J	2,500	$35.00
HIBBS KATHY L	1,250	$34.42
BAKER FELIX J	5,594	$34.75
BAKER FELIX J	17,822	$34.02
BAKER FELIX J	1,104	$34.75
BAKER FELIX J	3,516	$34.02
SCHORNO DEAN L	4,000	$36.02
SCHORNO DEAN L	4,000	$17.18
COLE GORDON BRADLEY	2,500	$1.33
COLE GORDON BRADLEY	2,500	$35.99
POPOVITS KIMBERLY J	2,500	$30.00
POPOVITS KIMBERLY J	2,500	$2.88
COLE GORDON BRADLEY	2,500	$1.33
COLE GORDON BRADLEY	2,500	$27.79

» Full list on Insider Trading

People: Genomic Health Inc (GHDX.O)

Related Topics:

Summary

Biographies

Basic Compensation

Options Compensation

Related Topics: